Goldenwell Biotech, Inc. Overview
Pro stress-test →Goldenwell Biotech focuses on nutraceutical and dietary supplements business in the United States. The company is developing JI MAI (a bovine cardiac vascular active peptide), Double Proline AG (a 3D active collagen peptide drinkable cosmetic), Cartilage Peptide (a Type II collagen peptide), and Sugar Master (a dietary supplement).
Strategic Profile
Pro stress-test →As of September 30, 2025, the company had trailing 12-month revenue of $62.5K. Management has identified substantial doubt about the company's ability to continue as a going concern due to its accumulated net loss of $1,331,643 since inception. In March 2026, Goldenwell Biotech filed an NT 10-K notification indicating it could not timely compile its Form 10-K for the year ended December 31, 2025, and expects to file by April 15, 2026.
Competitive Landscape
Pro stress-test →Goldenwell Biotech competes in the crowded nutraceutical and dietary supplement market against established brands. Direct competitors include large-cap supplement manufacturers and private label producers. The company's peptide-based formulations (collagen, bovine peptides) position it in the performance supplement segment, competing with brands like USANA, Herbalife, and smaller specialized peptide supplement makers. Limited market presence and severe capital constraints significantly disadvantage the company versus established competitors.
Industry Context
Goldenwell Biotech, Inc. operates in Dietary supplements and nutraceuticals.
Key facts
Founded: 2019 · Headquarters: Hudson, Ohio · Revenue: $62.5K · Market cap: $104M